NABRIVA THERAPEUTICS PLC - SHS NEW 2022 (NBRVF)

CUSIP: G63637139

Q1 2023 13F Holders as of 31 Mar 2023

Type / Class
Equity / SHS NEW 2022
Total 13F shares
86,438
Share change
-9,345
Total reported value
$150,695
Price per share
$1.75
Number of holders
11
Value change
-$18,598
Number of buys
7
Number of sells
3

Quarterly Holders Quick Answers

What is CUSIP G63637139?
CUSIP G63637139 identifies NBRVF - NABRIVA THERAPEUTICS PLC - SHS NEW 2022 in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of NABRIVA THERAPEUTICS PLC - SHS NEW 2022 (NBRVF) as of Q1 2023

As of 31 Mar 2023, NABRIVA THERAPEUTICS PLC - SHS NEW 2022 (NBRVF) was held by 11 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 86,438 shares. The largest 10 holders included Values First Advisors, Inc., RENAISSANCE TECHNOLOGIES LLC, Frazier Life Sciences Management, L.P., CITADEL ADVISORS LLC, MORGAN STANLEY, ADVISOR GROUP HOLDINGS, INC., UBS Group AG, FMR LLC, BANK OF AMERICA CORP /DE/, and WELLS FARGO & COMPANY/MN. This page lists 11 institutional shareholders reporting positions in this security for the Q1 2023 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.